With U.S. stocks at all-times highs, it can be a serious challenge to find growth vehicles that are still worth buying at these levels. To do so, I think investors may want to try to mine the depths of the small-cap biotechnology space to unearth compelling bargains. Some of these stocks, after all, are nearing pivotal catalysts that could drive their shares much higher next year and beyond.
Keeping with this theme, I'm personally considering adding Amarin (NASDAQ: AMRN), Novavax (NASDAQ: NVAX), and Dynavax Technologies Corporation (NASDAQ: DVAX) to my portfolio early next year. Here's why.
Image source: Getty Images.
Source: Fool.com